Targeting PRAME for acute myeloid leukemia therapy
Despite significant progress in targeted therapy for acute myeloid leukemia (AML), clinical outcomes are disappointing for elderly patients, patients with less fit disease characteristics, and patients with adverse disease risk characteristics. Over the past 10 years, adaptive T-cell immunotherapy h...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-03-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1378277/full |
| _version_ | 1827308911547383808 |
|---|---|
| author | Jinjun Yang Mengran Chen Jing Ye Hongbing Ma |
| author_facet | Jinjun Yang Mengran Chen Jing Ye Hongbing Ma |
| author_sort | Jinjun Yang |
| collection | DOAJ |
| description | Despite significant progress in targeted therapy for acute myeloid leukemia (AML), clinical outcomes are disappointing for elderly patients, patients with less fit disease characteristics, and patients with adverse disease risk characteristics. Over the past 10 years, adaptive T-cell immunotherapy has been recognized as a strategy for treating various malignant tumors. However, it has faced significant challenges in AML, primarily because myeloid blasts do not contain unique surface antigens. The preferentially expressed antigen in melanoma (PRAME), a cancer-testis antigen, is abnormally expressed in AML and does not exist in normal hematopoietic cells. Accumulating evidence has demonstrated that PRAME is a useful target for treating AML. This paper reviews the structure and function of PRAME, its effects on normal cells and AML blasts, its implications in prognosis and follow-up, and its use in antigen-specific immunotherapy for AML. |
| first_indexed | 2024-04-24T19:20:02Z |
| format | Article |
| id | doaj.art-c1327cd8794d4895b9da778ae8835be7 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-24T19:20:02Z |
| publishDate | 2024-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-c1327cd8794d4895b9da778ae8835be72024-03-26T04:22:21ZengFrontiers Media S.A.Frontiers in Immunology1664-32242024-03-011510.3389/fimmu.2024.13782771378277Targeting PRAME for acute myeloid leukemia therapyJinjun Yang0Mengran Chen1Jing Ye2Hongbing Ma3Department of Hematology and Institute of Hematology, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Hematology and Institute of Hematology, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Dermatology and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, ChinaDepartment of Hematology and Institute of Hematology, West China Hospital, Sichuan University, Chengdu, ChinaDespite significant progress in targeted therapy for acute myeloid leukemia (AML), clinical outcomes are disappointing for elderly patients, patients with less fit disease characteristics, and patients with adverse disease risk characteristics. Over the past 10 years, adaptive T-cell immunotherapy has been recognized as a strategy for treating various malignant tumors. However, it has faced significant challenges in AML, primarily because myeloid blasts do not contain unique surface antigens. The preferentially expressed antigen in melanoma (PRAME), a cancer-testis antigen, is abnormally expressed in AML and does not exist in normal hematopoietic cells. Accumulating evidence has demonstrated that PRAME is a useful target for treating AML. This paper reviews the structure and function of PRAME, its effects on normal cells and AML blasts, its implications in prognosis and follow-up, and its use in antigen-specific immunotherapy for AML.https://www.frontiersin.org/articles/10.3389/fimmu.2024.1378277/fullPRAMEacute myeloid leukemialeukemia-associated antigenminimal residual diseaseimmunotherapyadoptive T-cell therapy |
| spellingShingle | Jinjun Yang Mengran Chen Jing Ye Hongbing Ma Targeting PRAME for acute myeloid leukemia therapy Frontiers in Immunology PRAME acute myeloid leukemia leukemia-associated antigen minimal residual disease immunotherapy adoptive T-cell therapy |
| title | Targeting PRAME for acute myeloid leukemia therapy |
| title_full | Targeting PRAME for acute myeloid leukemia therapy |
| title_fullStr | Targeting PRAME for acute myeloid leukemia therapy |
| title_full_unstemmed | Targeting PRAME for acute myeloid leukemia therapy |
| title_short | Targeting PRAME for acute myeloid leukemia therapy |
| title_sort | targeting prame for acute myeloid leukemia therapy |
| topic | PRAME acute myeloid leukemia leukemia-associated antigen minimal residual disease immunotherapy adoptive T-cell therapy |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2024.1378277/full |
| work_keys_str_mv | AT jinjunyang targetingprameforacutemyeloidleukemiatherapy AT mengranchen targetingprameforacutemyeloidleukemiatherapy AT jingye targetingprameforacutemyeloidleukemiatherapy AT hongbingma targetingprameforacutemyeloidleukemiatherapy |